OmniAb, Inc. ( OABI ) Reports Q2 Loss, Lags Revenue Estimates
OmniAb, Inc. (OABI) delivered earnings and revenue surprises of -7.14% and -35.71%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Tharimmune Announces Key Leadership Appointments Including James Gordon Liddy Joining Board of Directors
Tharimmune, Inc. ( NASDAQ:THAR ) , a clinical-stage biotechnology company developing a portfolio of therapeutic candidates for inflammation and immunology, today announced significant appointments to its executive leadership and board of directors, reinforcing its commitment to advancing its ...
OmniAb, Inc. ( OABI ) Reports Q1 Loss, Misses Revenue Estimates
OmniAb, Inc. (OABI) delivered earnings and revenue surprises of 0% and 11.50%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
VERAXA Biotech Enters Co-discovery Alliance with OmniAb for a Novel Bispecific Antibody Drug Conjugate Program
Partnership Combines VERAXA's Proprietary ADC Technology with OmniAb's Antibody Discovery Technology for Novel Therapies Targeting Solid Tumors Partnership Combines VERAXA's Proprietary ADC Technology with OmniAb's Antibody Discovery Technology for Novel Therapies Targeting Solid Tumors ...
VERAXA Biotech Enters Co-discovery Alliance with OmniAb for a Novel Bispecific Antibody Drug Conjugate Program - Voyager Acquisition ( NASDAQ:VACH ) , OmniAb ( NASDAQ:OABI )
ZURICH, SWITZERLAND, May 5, 2025 -- VERAXA Biotech AG ( "VERAXA" ) , an emerging leader in designing novel cancer therapies and proposed de-SPAC acquisition target of Voyager Acquisition Corp. VACH "Voyager" ) ) , announced today a co-discovery alliance with OmniAb, Inc.
Tharimmune Abstracts Accepted for Presentation at Upcoming DDW and EASL Conferences
Tharimmune, Inc., ( Nasdaq:THAR ) ( "Tharimmune" or the "Company" ) a clinical-stage biopharmaceutical company focused on developing innovative therapeutics in inflammation & immunology announced abstracts featuring clinical data on its lead drug candidate, TH104, have been accepted for ...
Dow Surges Over 200 Points; US Crude Oil Inventories Increase More than Expected - BGM Group ( NASDAQ:BGM ) , Aterian ( NASDAQ:ATER )
U.S. stocks traded higher midway through trading, with the Dow Jones index gaining over 200 points on Wednesday. The Dow traded up 0.55% to 41,808.59 while the NASDAQ climbed 0.95% to 17,671.26. The S&P 500 also rose, gaining, 0.66% to 5,651.61. Energy shares rose by 1.2% on Wednesday.
OmniAb, Inc. ( OABI ) Reports Q4 Loss, Tops Revenue Estimates
OmniAb, Inc. (OABI) delivered earnings and revenue surprises of 7.69% and 18.21%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Nektar Therapeutics ( NKTR ) Q4 Earnings Miss Estimates ( Revised )
Nektar (NKTR) delivered earnings and revenue surprises of -15.38% and 25.23%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Nektar Therapeutics ( NKTR ) Q4 Earnings Beat Estimates
Nektar (NKTR) delivered earnings and revenue surprises of 215.38% and 25.23%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Verve Therapeutics ( VERV ) Reports Q4 Loss, Tops Revenue Estimates
Verve Therapeutics (VERV) delivered earnings and revenue surprises of 19.44% and 90.39%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
DAAN Biotherapeutics Signs Antibody Exclusive Licensing Agreement with LigaChem Biosciences for ADC ( Antibody-Drug Conjugate ) Therapeutic Development
SEOUL, South Korea, Feb. 13, 2025 /PRNewswire/ -- DAAN Biotherapeutics, a leading innovative drug development company specializing in T-cell receptor ( TCR ) - based therapies, has signed an exclusive licensing agreement with LigaChem Biosciences for a novel tumor-targeting antibody to advance ...
Single Domain Antibody Platform Market to Reach US$ 86 Million by 2034, Expanding at a CAGR of 10.1% | Fact.MR Report
Rockville, MD, Dec. 04, 2024 ( GLOBE NEWSWIRE ) -- Increasing investments in healthcare research and development are leading to the increased adoption of single domain antibody platforms due to their key role in improving the efficacy of treatments.
OmniAb, Inc. ( OABI ) Reports Q3 Loss, Lags Revenue Estimates
OmniAb, Inc. (OABI) delivered earnings and revenue surprises of -14.29% and 52.95%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Vaccinex Provides Update on ActivMAb® Platform: Multiple Project Deals and Presentation at SITC
Partnerships will employ Vaccinex's ActivMAb® tech. Successful antibody discovery campaigns for cancer immunotherapy to be presented at SITC Nov 9, 2024.
Aurinia Pharmaceuticals ( AUPH ) Q3 Earnings and Revenues Beat Estimates
Aurinia (AUPH) delivered earnings and revenue surprises of 400% and 14.74%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
The Benchmark Company Announces Upcoming Healthcare House Call VIRTUAL One-on-One Investor Conference
NEW YORK, May 06, 2024 ( GLOBE NEWSWIRE ) -- The Benchmark Company is pleased to announce our upcoming Healthcare House Call VIRTUAL One-on-One Investor Conference happening on Tuesday & Wednesday, May 21st - 22nd, 2024.
USANA Health Sciences ( USNA ) Q1 Earnings and Revenues Top Estimates
USANA Health (USNA) delivered earnings and revenue surprises of 24.64% and 2.03%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Over $1M Bet On OmniAb? Check Out These 3 Stocks Insiders Are Buying - Hallador Energy ( NASDAQ:HNRG ) , OmniAb ( NASDAQ:OABI )
Although U.S. stocks closed lower on Monday, there were a few notable insider trades. When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the stock as a bargain. Either way, this signals an opportunity to go long on the stock.
Plus Therapeutics ( PSTV ) Reports Q4 Loss, Tops Revenue Estimates
Plus (PSTV) delivered earnings and revenue surprises of 10.26% and 4.21%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Karyopharm Therapeutics ( KPTI ) Reports Q4 Loss, Tops Revenue Estimates
Karyopharm Therapeutics (KPTI) delivered earnings and revenue surprises of -24.14% and 0.74%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
OmniAb, Inc. ( OABI ) Soars 10.5%: Is Further Upside Left in the Stock?
OmniAb, Inc. (OABI) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Aclaris Therapeutics ( ACRS ) Reports Q4 Loss, Tops Revenue Estimates
Aclaris (ACRS) delivered earnings and revenue surprises of 18.92% and 344.14%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Zacks Industry Outlook Highlights Gilead Sciences, CRISPR Therapeutics, ACADIA Pharmaceuticals, Dynavax and Ligand Pharmaceuticals
Gilead Sciences, CRISPR Therapeutics, ACADIA Pharmaceuticals, Dynavax and Ligand Pharmaceuticals are part of the Zacks Industry Outlook article.
5 Biotech Stocks Likely to Thrive as Industry Prospects Look Bright
New drug approvals and pipeline progress are likely to help maintain momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and solid pipeline progress position GILD, CRSP, ACAD, DVAX and LGND well amid volatility.
OmniAb President and CEO Trades Company's Stock - OmniAb ( NASDAQ:OABI )
Matthew W Foehr, President and CEO at OmniAb OABI, reported a large insider buy on November 13, according to a new SEC filing. What Happened: A Form 4 filing from the U.S. Securities and Exchange Commission on Monday showed that Foehr purchased 95,000 shares of OmniAb. The total transaction ...
Hillstream Enters into an Exclusive Option Agreement to Acquire a Clinical Stage Asset for Chronic Pruritis - Hillstream BioPharma ( NASDAQ:HILS )
Anticipate completion of Phase 1 & Phase 2 clinical trials in chronic pruritis over the next approximately 12 months Seeking first approval in an orphan disease, PBC, for the treatment of moderate to severe chronic pruritis in which more than 70% of patients suffer from chronic pruritis
Hillstream BioPharma to Present at H.C. Wainwright 25th Annual Global Investment Conference September 11-13
BRIDGEWATER, N.J., Sept. 08, 2023 ( GLOBE NEWSWIRE ) -- Hillstream BioPharma, Inc. ( Nasdaq: HILS ) ( "Hillstream" or the "Company" ) , a biotechnology company developing therapeutic candidates targeting drug resistant and devastating cancers with immuno-oncology targeted novel biologics, today ...
Hillstream BioPharma to Present at H.C. Wainwright 25th Annual Global Investment Conference September 11-13 - Hillstream BioPharma ( NASDAQ:HILS )
Management will present and hold virtual 1-on-1 meetings with institutional investors and analysts BRIDGEWATER, N.J., Sept. 08, 2023 ( GLOBE NEWSWIRE ) -- Hillstream BioPharma, Inc.
Hillstream BioPharma to Present at the Sidoti Micro-Cap Virtual Conference on August 16-17, 2023
BRIDGEWATER, N.J., Aug. 09, 2023 ( GLOBE NEWSWIRE ) -- Hillstream BioPharma, Inc. ( Nasdaq: HILS ) ( "Hillstream" or the "Company" ) , a biotechnology company developing therapeutic candidates targeting drug resistant and devastating cancers using ferroptosis, an emerging new anti-cancer ...
Hillstream BioPharma to Present at the Sidoti Micro-Cap Virtual Conference on August 16-17, 2023 - Hillstream BioPharma ( NASDAQ:HILS )
Management will present and hold virtual 1-on-1 meetings with institutional investors and analysts Company recently announced license and collaboration expansions for next-gen multispecific antibodies for solid tumors with lead HER2/HER3 program, HSB-3215, in collaboration with OmniAb, Inc. and ...
Ligand ( LGND ) to Post Q2 Earnings: What's in Store?
Ligand's (LGND) second-quarter 2023 performance is likely to have been driven by rising royalty revenues on the back of higher growth in sales of drugs developed using its pelican platform.
Cadence Design and Ligand have been highlighted as Zacks Bull and Bear of the Day
Chicago, IL - July 21, 2023 - Zacks Equity Research shares Cadence Design Systems ( CDNS Quick QuoteCDNS - ) as the Bull of the Day and Ligand Pharmaceuticals ( LGND Quick QuoteLGND - ) as the Bear of the Day.
Bear of the Day: Ligand Pharmaceuticals ( LGND )
Ligand is an innovative Bio-Pharma M&A royalty-generator, but the model is volatile ...
5 Biotech Stocks to Buy as Industry Prospects for 2H23 Look Good
New drug approvals and pipeline progress are likely to help maintain momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and a solid pipeline progress position PCVX, PTGX, LGND, MESO and PBYI well amid volatility.
7 Hot Penny Stocks To Buy In May According To Insiders
Penny stocks are typically sought after in hopes of discovering hidden potential. In this article, we look at recent insider buying and see if there are any current or upcoming events worth noting to prompt insider action.
Stratasys, Navitas Semiconductor, United Insurance And Other Big Stocks Moving Higher On Tuesday - Archer Aviation ( NYSE:ACHR ) , Advantage Solutions ( NASDAQ:ADV )
Applied Digital Corporation APLD jumped 44.6% to $4.94 after the company announced that its recently launched AI Cloud Service has secured its first major AI customer with an agreement worth up to $180 million over a 24-month period.
$1.5M Bet On This Healthcare Stock? Check Out These 3 Penny Stocks Insiders Are Aggressively Buying - Citizens ( NYSE:CIA ) , OmniAb ( NASDAQ:OABI )
The Dow Jones closed higher on Monday after recording losses last week. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or ...
Ligand ( LGND ) Up 3% on Raised '23 View, Beats on Q1 Earnings
Ligand Pharmaceuticals (LGND) announces better-than-expected results in first-quarter 2023. Management raises 2023 financial outlook.
Here's How Much a $1000 Investment in Ligand Pharmaceuticals Made 10 Years Ago Would Be Worth Today
Holding on to popular or trending stocks for the long-term can make your portfolio a winner.
Here's Why You Should Add Ligand ( LGND ) Stock to Your Portfolio
Ligand's (LGND) proprietary platforms enable it to form partnerships with several leading drug companies, providing it with funds through milestone and royalty payments.
Do Options Traders Know Something About OmniAb ( OABI ) Stock We Don't?
Investors need to pay close attention to OmniAb (OABI) stock based on the movements in the options market lately.
The Increasing Prevalence Of Cancer Is Among The Major Growth Drivers For The Bi-Specific MAbs Market - By The Business Research Company
The Increasing Prevalence Of Cancer Is Among The Major Growth ... PR ...
Zacks Industry Outlook Highlights CRISPR Therapeutics, Ligand Pharmaceuticals, Theseus Pharmaceuticals and Kala Pharmaceuticals
CRISPR Therapeutics, Ligand Pharmaceuticals, Theseus Pharmaceuticals and Kala Pharmaceuticals are part of the Zacks Industry Outlook article.
4 Biotech Stocks to Consider for Your Portfolio in 2023
New drug approvals and pipeline progress should maintain the momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and a solid pipeline progress position CRSP, LGND, THRX and KALA well amid volatility.
Ligand's ( LGND ) Q4 Sales & Earnings Top, View Raised, Stock Up
Ligand Pharmaceuticals (LGND) announces better-than-expected results in fourth-quarter 2022. Stock is up in the after-market hours in response to the news. Management raises 2023 financial outlook.
5 Penny Stocks With Explosive Price Targets & Buy Ratings From Analysts
Penny Stocks To Buy According To Analysts As the stock market continues to become more and more unpredictable, it's increasingly important for traders to use every available tool. Whether you're trading penny stocks or higher-priced shares, one of those tools is analyst insight.
Some 'Transgenic Animal Platforms Are More Than Equal,' Analyst Initiating Coverage On OmniAb Says - OmniAb ( NASDAQ:OABI )
Credit Suisse initiated coverage on OmniAb Inc OABI with an Outperform rating and a price target of $13. The company is spun off of Ligand Pharmaceuticals Inc's LGND antibody discovery business.
Ligand Pharma Issues Mixed Guidance For FY23 - Ligand Pharmaceuticals ( NASDAQ:LGND )
At its Investor and Analyst Day event, Ligand Pharmaceuticals Incorporated LGND provided an overview of Ligand's corporate structure and business following the successful spin-off of its OmniAb antibody discovery business. Management also introduced 2023 financial guidance.
Penny Stocks To Buy Now? 3 Low Float Stocks Under $1 To Watch
One of the exciting things about penny stocks is that they can break out big even if the stock market is down. On top of that, it doesn't take any significant catalyst to spark a rally. Many catalysts that trigger a retail trading frenzy have less to do with companies directly and more to do with ...
